- E16.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2024 edition of ICD-10-CM E16.3 became effective on October 1, 2022.
- This is the American ICD-10-CM version of E16.3 – other international versions of ICD-10 E16.3 may differ.
ICD-10-CM E16.3 is grouped within Diagnostic Related Group(s):
- 643 Endocrine disorders with mcc
- 644 Endocrine disorders with cc
- 645 Endocrine disorders without cc/mcc
Applicable To
- Hyperplasia of pancreatic endocrine cells with glucagon excess
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2016 (effective 10/1/2015): No change
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2024 (effective 10/1/2022): No change
Diagnosis Index entries containing back-references to E16.3:
- glucagon secretion > Abnormal, abnormality, abnormalities
- glucagon > secretion E16.4
- glucagon > Excess, excessive, excessively
- glucagon > with excess E16.4
- glucagon > Hypersecretion
- glucagon > secretion E16.4